Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma

K. Matsuo, K. Takenaka, H. Shimomura, N. Fujii, K. Shinagawa, K. Kiura, M. Harada

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We report a chronic hepatitis B virus (HBV) carrier with non-Hodgkin lymphoma (NHL) who developed HBV hepatitis following conventional dose chemotherapy and was successfully treated with lamivudine and glycyrrhizin. A 55 year-old male patient with primary testicular NHL (diffuse large B-cell type) relapsed. During the salvage chemotherapy, the patient showed elevated serum levels of transaminase and HBV-DNA due to HBV reactivation. Treatment with lamivudine, an antiviral nucleoside analog, was started at a dose of 100mg/day. Shortly after the treatment the HBV-DNA level was suppressed, and sustained elevation of transaminase levels were normalized after additional treatment with glycyrrhizin. This experience suggests that lamivudine combined with glycyrrhizin may be effective for controlling HBV replication and treating chemotherapy-induced HBV hepatitis in chronic HBV carriers with NHL.

Original languageEnglish
Pages (from-to)191-195
Number of pages5
JournalLeukemia and Lymphoma
Volume41
Issue number1-2
DOIs
Publication statusPublished - Jan 1 2001
Externally publishedYes

Keywords

  • Chemotherapy induced hepatitis
  • Glycyrrhizin
  • Hepatitis B carrier
  • Lamivudine
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this